iA Global Asset Management Inc. Buys 9,476 Shares of Boston Scientific Corporation $BSX

iA Global Asset Management Inc. boosted its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 5.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 172,207 shares of the medical equipment provider’s stock after buying an additional 9,476 shares during the quarter. iA Global Asset Management Inc.’s holdings in Boston Scientific were worth $18,497,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in BSX. Bessemer Group Inc. grew its position in Boston Scientific by 14,391.8% during the second quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after buying an additional 2,899,653 shares during the period. Vanguard Group Inc. grew its position in Boston Scientific by 1.3% during the first quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider’s stock valued at $13,577,311,000 after buying an additional 1,697,945 shares during the period. Price T Rowe Associates Inc. MD grew its position in Boston Scientific by 18.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 10,610,487 shares of the medical equipment provider’s stock valued at $1,070,387,000 after buying an additional 1,664,108 shares during the period. Swedbank AB grew its position in Boston Scientific by 114.5% during the second quarter. Swedbank AB now owns 2,819,249 shares of the medical equipment provider’s stock valued at $302,816,000 after buying an additional 1,505,019 shares during the period. Finally, Goldman Sachs Group Inc. grew its position in Boston Scientific by 10.8% during the first quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider’s stock valued at $1,426,779,000 after buying an additional 1,383,524 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other news, Director Ellen M. Zane sold 9,990 shares of the business’s stock in a transaction on Monday, October 27th. The shares were sold at an average price of $101.13, for a total value of $1,010,288.70. Following the transaction, the director owned 27,035 shares of the company’s stock, valued at approximately $2,734,049.55. The trade was a 26.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The stock was sold at an average price of $98.47, for a total transaction of $4,923,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares in the company, valued at $17,561,336.74. This trade represents a 21.90% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 112,891 shares of company stock worth $11,501,887 in the last three months. Insiders own 0.50% of the company’s stock.

Boston Scientific Price Performance

BSX stock opened at $100.81 on Friday. Boston Scientific Corporation has a one year low of $83.38 and a one year high of $109.50. The company’s fifty day moving average price is $100.76 and its 200-day moving average price is $102.35. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market capitalization of $149.37 billion, a PE ratio of 53.91, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the previous year, the firm earned $0.63 earnings per share. The company’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages recently issued reports on BSX. Erste Group Bank lowered shares of Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Truist Financial boosted their target price on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Evercore ISI reiterated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. Wall Street Zen upgraded shares of Boston Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 11th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Friday, October 17th. Two analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.